Post-marketing Pharmacovigilance

With the study of pre-authorised medicines usually limited to the relatively small number of patients covered during clinical trials, it is essential that once a medicine receives its marketing authorisation, the monitoring process continues throughout its lifecycle to ensure the benefit-risk remains appropriate and any adverse drug reactions are reported and acted on appropriately.

For more information on Post-marketing Pharmacovigilance talk to PharmaLex UK Services Limited